Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2

Rigshospitalet, Denmark406 enrolled

Overview

Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease. Patients are randomised to surgery or not.

Patients are after staging randomised to neoadj. chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation. Endpoint is survival.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

406

Conditions

Non-Small Cell Lung Cancer

Interventions

SurgeryPROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically verified NSCLC * Stage IIIA/N2 * age 18-75 * Lung function test allowing surgery * Mediastinoscopy performed Exclusion Criteria: * Prior chemotherapy * Prior irradiation

Locations (1)

Dept. Oncology, Rigshospitalet

Copenhagen, Copenhagen, Denmark

RECRUITING

Outcomes

Primary Outcomes

Survival

Secondary Outcomes

time to progression

Central Contacts

Jens B. Sorensen, MD

CONTACT

35454372 jbsonk@rh.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.